We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Ekterly JACE Pharma Pty Ltd
Product name
Ekterly
Sponsor
Accepted date
Oct-2024
Active ingredients
Sebetralstat
Proposed indication
Ekterly (sebetralstat) is for the treatment of hereditary angioedema (HAE) attacks (swelling in different parts of the body due to C1-inhibitor inactivity) in adults and adolescents aged 12 years and older.
Application type
A (new medicine)
Publication date
Oct-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.